The U.S. Food and Drug Administration granted 510(k) clearance (K260005) for HeartSciences' MyoVista wav ECG device, allowing it to function as a 12-lead resting electrocardiograph for adult and pediatric patients. The clearance covers signal acquisition and advisory interpretive statements but excludes the company's AI-ECG algorithm. Management stated there is no timeline for commercializing the hardware without the cleared algorithm, though the approval broadens options for realizing value from the device's intellectual property. Concurrently, the proposed business combination with Fortitude Mining Holdings continues to progress toward a closing expected in Q4 2026, subject to shareholder approval and customary conditions. HeartSciences is a healthcare information technology company advancing electrocardiography through artificial intelligence integration.
